Indicate by check mark whether
the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
DBV TECHNOLOGIES S.A.
|
|
|
|
|
Date: March 26, 2018
|
|
|
|
By:
|
|
/s/ David Schilansky
|
|
|
|
|
Name
|
|
David Schilansky
|
|
|
|
|
Title:
|
|
Deputy Chief Executive Officer
|
Exhibit 99.1
DBV Technologies Announces Closing of Underwriters Option to Purchase Additional Shares in Global Offering
DBV Technologies (the Company) (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced the issuance and the settlement and delivery of an aggregate of an additional 529,162 ordinary shares, including 208,802 ordinary shares in the form of 417,604 ADSs, on the same terms and conditions as the
securities previously sold in the global offering, pursuant to the exercise of the underwriters option to purchase additional ordinary shares, including in the form of American Depositary Shares (ADSs), in the Companys previously
announced global offering (the Option Closing). Each ADS represents the right to receive
one-half
of one ordinary share. Following the Option Closing, the gross proceeds to the Company from the
global offering are approximately $172.5 million (approximately 140.8 million), before deducting underwriting commissions and estimated offering expenses. The ADSs are listed on the Nasdaq Global Select Market under the
symbol DBVT, and the Companys ordinary shares are listed on Euronext Paris under the symbol DBV.
Morgan Stanley and
Goldman Sachs acted as joint lead book-running managers for the global offering. Barclays and Deutsche Bank Securities also served as book-running managers. Bryan, Garnier & Co. acted as a
co-manager
for the global offering.
The Company plans to use the net proceeds from the global offering to fund the development and commercialization of Viaskin
Peanut, to advance development of its other product candidates and for working capital and general corporate purposes.
A registration statement on Form
F-3
relating to the securities to be issued in the global offering was filed with the Securities and Exchange Commission and became automatically effective on July 27, 2016. The public offering was made only by
means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the Securities and
Exchange Commission and is available on the Securities and Exchange Commissions website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained for free from: Morgan Stanley & Co.
LLC, 180 Varick Street, 2nd Floor, New York, New York 10014, United States, Attention: Prospectus Department; Goldman Sachs, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone:
1-866-471-2526,
facsimile:
212-902-9316
or via email:
prospectusgroup-ny@ny.email.gs.com
; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by phone at
1-888-603-5847
or by
e-mail
at:
barclaysprospectus@broadridge.com
; or Deutsche Bank Securities: 60 Wall Street, New York,
New York 10005-2836, Attention: Prospectus Group, Telephone: (800)
503-4611,
E-mail:
prospectus.cpdg@db.com
.
* *
*
About DBV Technologies
DBV Technologies
is developing Viaskin
®
, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT
®
, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and
non-invasive
product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBVs food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human
proof-of-concept
clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The
Companys ordinary shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Companys ADSs (each representing
one-half
of one
ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward Looking Statements
This press release contains forward-looking statements, including statements about the anticipated use of proceeds from the offering. These forward-looking
statements are not promises or guarantees and involve substantial risks and uncertainties. Factors that could cause actual results to differ materially from those described or projected herein include risks associated with clinical trials and
regulatory reviews and approvals, and risk related to the sufficiency of the Companys existing cash resources and liquidity. A further list and description of these risks, uncertainties and other risks can be found in the Companys
regulatory filings with the French Autorité des Marchés Financiers and U.S. Securities and Exchange Commission, including in the Companys Annual Report on Form
20-F
for the year ended
December 31, 2017. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise
forward-looking statements as a result of new information, future events or circumstances, or otherwise, except as required by law.
Contact
Sara Blum Sherman
Senior Director, Investor Relations &
Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com
Disclaimers
This press release does not constitute an
offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
The distribution of this document may, in certain jurisdictions, be restricted by local legislations.
Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.
No
prospectus subject to approval by the French Autorité des Marchés Financiers (AMF) has been filed in connection with the global offering. Copies of the Companys Reference Document, including the risk factors, registered by the
AMF on March 16, 2018 under No.
D.18-0144
are available for free at the Companys head office located at: 177-,181, avenue Pierre Brossolette 92120 Montrouge, France, and on the AMFs
website at
www.amf-france.org.
This document does not constitute an offer to the public in France and the securities referred to in this
document can only be offered or sold in France pursuant to article L.
411-2-II
of the French Monetary and Financial Code to (i) providers of third party portfolio
management investment services, (ii) qualified investors (investisseurs qualifiés) acting for their own account and/or (iii) a limited group of investors (cercle restreint dinvestisseurs) acting for their own account, all as
defined in and in accordance with articles L.
411-1,
L.
411-2
and D.
411-1
to D.
411-4
and D.
754-1
and D.
764-1
of the French Monetary and Financial Code.
This
announcement is not an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003, as amended (the Prospectus Directive).
With respect to the member States of the European Economic Area, no action has been undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any relevant member State. As a result, the securities may not and will not be offered in any relevant member State except in accordance with the exemptions set forth in
Article 3(2) of the Prospectus Directive or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member
State.
This document is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are investment
professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the Order), (ii) are persons falling within Article 49(2)(a) to (d) (high net worth
companies, unincorporated associations, etc.) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in
connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as Relevant Persons). This document is directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.